Fangzhou Inc. has launched Novo Nordisk’s Kyinsu® on its Internet hospital platform in China, making the once-weekly basal insulin and GLP-1 receptor agonist combination therapy available through its AI-enabled chronic disease management ecosystem.

• Therapy Composition: Kyinsu® combines once-weekly insulin icodec with semaglutide, a GLP-1 receptor agonist, to target multiple pathophysiological mechanisms involved in type 2 diabetes.
• Administration: The once-weekly formulation reduces injection frequency from daily to weekly, aiming to lower treatment burden while maintaining glycaemic control.
• Digital Care Integration: The therapy is supported by Fangzhou’s AI-powered Hospital-to-Home (AI+H2H) platform, which integrates digital follow-up, medication guidance, patient education, and pharmaceutical supply chain services for long-term diabetes management.

This summary is based on a news article published by BioSpectrum Asia.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.